Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Shares | 100.000 | 100.000 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 20.743 | 21.748 |
Price to Book | 4.794 | 4.013 |
Price to Sales | 2.438 | 2.262 |
Price to Cash Flow | 15.295 | 16.964 |
Dividend Yield | 1.596 | 1.339 |
5 Years Earnings Growth | 12.429 | 11.136 |
Name | Net % | Category Average |
---|---|---|
Healthcare | 95.640 | 94.942 |
Industrials | 2.040 | 3.307 |
Basic Materials | 1.390 | 1.277 |
Consumer Defensive | 0.930 | 3.344 |
Number of long holdings: 44
Number of short holdings: 0
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
UnitedHealth | US91324P1021 | 10.36 | 492.66 | -0.06% | |
Roche Holding Participation | CH0012032048 | 6.97 | 217.30 | +1.49% | |
Novo Nordisk A/S Class B | DK0060534915 | 6.87 | - | - | |
Amgen | US0311621009 | 6.18 | 311.34 | +11.84% | |
Elevance Health | US0367521038 | 5.54 | 527.01 | +0.27% | |
Vertex | US92532F1003 | 5.01 | 401.08 | +0.23% | |
Pfizer | US7170811035 | 4.04 | 27.83 | +0.47% | |
GSK plc | GB00BN7SWP63 | 3.51 | 1,733.50 | +0.29% | |
Veeva Systems A | US9224751084 | 3.22 | 203.45 | +1.00% | |
Regeneron Pharma | US75886F1075 | 3.21 | 957.00 | +2.07% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
American Growth Portfolio C Acs | 7.85B | 13.06 | 9.86 | 14.34 | ||
Thematic Research Portfolio S SGD A | 6.44B | 8.29 | 20.72 | 12.07 | ||
American Growth Portfolio A Acs | 7.21B | -25.83 | 11.14 | 14.09 | ||
Thematic Research Portfolio S1X Acs | 2.77B | 10.14 | 21.69 | 12.12 | ||
Thematic Research Portfolio SX Accs | 3.45B | 10.51 | 22.54 | 12.86 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review